Platinum Analogues
Showing 1 - 25 of 2,046
CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in
Completed
- Small Cell Lung Cancer
- +4 more
- CPT-11
- Platinum analogues
-
Tokorozawa, JapanDepartment of Obstetrics and Gynecology, National Defense Medica
May 21, 2019
Chemo-induced Peripheral Neuropathy, Colorectal Cancer Trial in Ankara (Hand-foot exercises)
Completed
- Chemotherapy-induced Peripheral Neuropathy
- Colorectal Cancer
- Hand-foot exercises
-
Ankara, Ankara/Keçiören, TurkeyGülhane Training and Resarch Hospital
May 24, 2023
Somatostatin Receptors and GH Receptor Expression on Bone of
Completed
- Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients
- Trans-sphenoidal surgery
-
Roma, ItalyFondazione Policlinnico Gemelli IRCCS
Apr 6, 2023
Chronic Hepatitis B Trial (HRS9950 tablets, HRS9950 tablets)
Not yet recruiting
- Chronic Hepatitis B
- HRS9950 tablets
- HRS9950 placebo tablets
- (no location specified)
Jun 7, 2023
Chronic Hepatitis b Trial in Chongqing, Xi'an (Placebo, TQA3605 tablets, Entecavir dispersible tablets)
Recruiting
- Chronic Hepatitis b
- Placebo
- +4 more
-
Chongqing, Chongqing, China
- +2 more
Nov 27, 2023
Long-term Oral Anti Hepatitis B Nucleoside Analogs and Hepatic
Enrolling by invitation
- Hepatic Steatosis
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital of Chongqing Medical University
Jun 9, 2022
NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Jun 26, 2023
Platinum-resistant Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- pegylated liposomal doxorubicin
- (no location specified)
Aug 2, 2023
Triple Negative Breast Cancer Trial in Dhaka (Doxorubicin, Cyclophosphamide, Paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Doxorubicin
- +3 more
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
May 24, 2023
Real-world Study Optimizing Nucleotide-analogues
Recruiting
- Hepatitis B, Chronic
-
Hefei, Anhui, China
- +43 more
Jul 7, 2023
Small Cell Lung Carcinoma Trial in Worldwide (Pembrolizumab/Vibostolimab Co-Formulation, Saline , Etoposide)
Recruiting
- Small Cell Lung Carcinoma
- Pembrolizumab/Vibostolimab Co-Formulation
- +5 more
-
Los Angeles, California
- +122 more
Jan 27, 2023
Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)
Not yet recruiting
- Ovarian Cancer
- (no location specified)
Jul 20, 2023
Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)
Active, not recruiting
- Non-Small-Cell Lung Carcinoma
- Pembrolizumab 200 mg
- +7 more
-
Nagoya, Aichi, Japan
- +9 more
Jan 23, 2023
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
GSTP1 and Other Gene Polymorphisms With Platinum-induced
Not yet recruiting
- Non-small Cell Lung Cancer
- GSTP1 A313G （AA）
- (no location specified)
Nov 16, 2023
NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,
Not yet recruiting
- Non-small Cell Lung Cancer
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
-
Tianjing, Tianjin, ChinaTianjin cancer hospital
Nov 3, 2023
Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or
Not yet recruiting
- Non-squamous Non-small-cell Lung Cancer
- Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
May 5, 2023
Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)
Not yet recruiting
- Ovarian Cancer Recurrent
- Fluzopril Combined With Apatinib
- (no location specified)
Oct 22, 2023
Metastatic Non-squamous Non Small Cell Lung Cancer Trial in Worldwide (Cosibelimab, Cisplatin, Carboplatin)
Active, not recruiting
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Cosibelimab
- +6 more
-
Vitória, Brazil
- +21 more
Aug 17, 2022
Extensive-stage Small-cell Lung Cancer Trial in Pittsburgh (Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection,
Not yet recruiting
- Extensive-stage Small-cell Lung Cancer
- Durvalumab 50 MG/1 ML Intravenous Solution
- +4 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Oct 31, 2022
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
Carcinoma, Small Cell Lung Trial in United States (RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide)
Terminated
- Carcinoma, Small Cell Lung
- RRx-001 + eLOOP Device
- Cisplatin/carboplatin plus etoposide
-
Denver, Colorado
- +17 more
Sep 30, 2022
Carcinoma, Small Cell Lung Trial in United States (RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide)
Active, not recruiting
- Carcinoma, Small Cell Lung
- RRx-001 + eLOOP Device
- Cisplatin/carboplatin plus etoposide
-
Tampa, Florida
- +5 more
Oct 3, 2022
Cancer of Unknown Primary Site Trial in Worldwide (Alectinib, Vismodegib, Ipatasertib)
Active, not recruiting
- Cancer of Unknown Primary Site
- Alectinib
- +17 more
-
Blacktown, New South Wales, Australia
- +140 more
Jan 6, 2023
Cancer, Ototoxicity, Drug-Induced, Quality of Life Trial (Patients suffering from chemo-induced ototoxicity)
Not yet recruiting
- Cancer
- +3 more
- Patients suffering from chemotherapy-induced ototoxicity
- (no location specified)
Jun 29, 2023